A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.

Key facts

Study ID
NCT05865171
Run by
Vertex Pharmaceuticals Incorporated
People needed
16
Starts
2023-06-12
Expected to finish
2024-06-12
Last updated by the study team
2024-07-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.